Novo Nordisk is expanding its production of hemophilia products with a new 7,500 square meter facility in Kalundborg, Denmark.
The Danish pharmaceutical company said on Monday that it will invest 1.5 billion Danish kroner ($225 million) in the manufacturing plant, which will produce active pharmaceutical ingredients for NovoSeven, its first hemophilia treatment, as well as future products for treating the rare blood disorder.
Novo Nordisk already employs more than 2,800 people in Kalundborg. This new facility will create another 100 production and engineering jobs.
"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees," said Henrik Wulff, executive vice president for product supply at Novo Nordisk.
Construction work for the new plant started this week. The facility is expected to be approved and fully operational in 2020.
The news comes less than three weeks after Bayer HealthCare said that it would invest $100 million in its hemophilia treatment production site in Berkeley, California, adding a product testing facility to support its next generation of treatments for patients with hemophilia A.
This facility will test Bayer's investigational products in accordance with rigorous global regulatory requirements, explained David Weinreich, MD, head of global development, Specialty Medicine at Bayer.